Beam Therapeutics, Codex DNA rise on Pfizer partnership

Telesis Bio

10/01/2022 13:06

(Updates)
    ** Shares of biotech cos Beam Therapeutics  BEAM.O  and
Codex DNA  DNAY.O  jump after signing collaboration agreements
with Pfizer  PFE.N 
    ** Beam to partner with drugmaker Pfizer Inc  PFE.N  in a
deal worth up to $1.35 bln deal to develop therapies for rare
genetic diseases; To receive $300 mln in upfront payment 
 urn:newsml:reuters.com:*:nL4N2TN2WE 
    ** BEAM entitled to 35% of the total net profits and costs
if it chooses to co-develop and co-commercialize any target with
PFE; BEAM up 5% at $73.98
    ** PFE also partners with synthetic biology co Codex DNA
 DNAY.O  to access and advance DNAY’s technology platform to
develop its mRNA-based vaccines and other biopharma products
 urn:newsml:reuters.com:*:nGNX3kFzs9 
    ** DNAY jumps ~30% to $12.21 premarket- set to open at its
highest in nearly four months
    ** PFE also enters into a deal with biotech co Acuitas
Therapeutics, under which PFE to have the option to license, on
a non-exclusive basis, Acuitas’ technology for up to 10 targets
for vaccine or therapeutic development  urn:newsml:reuters.com:*:nBwvNLNja 


 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))